Oxyntomodulin

What is Oxyntomodulin?

Oxyntomodulin (OXM) is a 37-amino-acid peptide hormone encoded within the same preproglucagon gene that produces glucagon, GLP-1, and GLP-2. It is released postprandially from intestinal L-cells and contains the full 29-residue glucagon sequence with an 8-residue C-terminal extension. Pharmacologically, OXM is a natural dual agonist at the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR) — the physiological template that later inspired the dual-agonist drug class (cotadutide / MEDI0382, survodutide, mazdutide). Human clinical studies from the Bloom laboratory at Imperial College London demonstrated that subcutaneous native OXM suppresses appetite, reduces energy intake, increases energy expenditure, and produces modest weight loss over short dosing windows. Native OXM has not been developed into an approved drug because its minutes-scale half-life makes chronic dosing impractical, but its receptor signature underpins most of the modern dual-agonist pipeline.

What Oxyntomodulin Is Investigated For

Oxyntomodulin is discussed almost entirely as a physiological prototype rather than a prescribable drug. Its historical importance is disproportionate to its commercial footprint: a series of early-2000s and mid-2000s studies from Stephen Bloom's group at Imperial College London — Cohen et al. (2003), Wynne et al. (2005 Diabetes, 2006 International Journal of Obesity) — established that intravenous and subcutaneous native OXM reduces hunger, cuts ad libitum food intake, increases energy expenditure, and produces ~2.3 kg weight loss over four weeks of thrice-daily subcutaneous dosing in overweight and obese volunteers. Subsequent mechanistic work (Shankar et al., Diabetes 2018) confirmed glucoregulatory effects in obese humans with and without type 2 diabetes that were independent of weight loss, supporting the dual GLP-1R/GCGR receptor model. The strongest evidence is therefore for the proof-of-concept — that balanced GLP-1/glucagon agonism produces greater weight loss and energy expenditure than GLP-1 agonism alone — rather than for OXM itself as therapy. The honest caveats: native OXM has a minutes-scale half-life and requires multiple daily injections, trial durations are short (days to 4 weeks), there is no Phase 3 program for native OXM, and the weight-management products that actually reach patients (cotadutide, survodutide, mazdutide, retatrutide) are engineered long-acting analogs, not native OXM. Anyone encountering 'oxyntomodulin' for sale online is not buying an approved drug.

History & Discovery

Oxyntomodulin was first identified in the late 1970s and early 1980s as a 37-amino-acid peptide detectable in intestinal extracts that stimulated oxyntic (acid-secreting) cells of the gastric mucosa — hence 'oxyntomodulin.' Early work by Bataille, Tager, and colleagues characterized its structure as the full 29-residue glucagon sequence plus an 8-residue C-terminal extension, and established that it was a product of the same preproglucagon gene, cleaved in intestinal L-cells rather than pancreatic alpha cells. For roughly two decades OXM was studied primarily as a curiosity of gut endocrinology. The modern therapeutic story begins at Imperial College London, where Stephen Bloom's group systematically investigated the appetite- and energy-regulating actions of gut peptides. In 2003, Mark Cohen and colleagues published the first human study showing that intravenous OXM suppresses appetite and reduces food intake (J Clin Endocrinol Metab 2003). In 2005, Katie Wynne, Adrian Park, and colleagues from the same group published the landmark 4-week double-blind randomized controlled trial (Diabetes 2005) in which subcutaneous OXM administered three times daily before meals produced 2.3 kg mean weight loss compared with 0.5 kg on placebo. A follow-up crossover trial (Int J Obes 2006) showed OXM also increases energy expenditure, establishing the dual-mechanism model of appetite suppression plus energy expenditure that defined the peptide's therapeutic rationale. Native OXM itself was never developed into an approved drug — its minutes-scale half-life required multiple daily injections, which was clinically impractical compared with emerging long-acting GLP-1 agonists. Instead, the receptor signature it exemplified — balanced GLP-1R and GCGR agonism — became the template for a new drug class. MedImmune (later AstraZeneca) developed MEDI0382, renamed cotadutide, as the first engineered long-acting OXM-inspired dual agonist; Phase 2a data were published in The Lancet in 2018. Boehringer Ingelheim developed survodutide (BI 456906), now in Phase 3 for obesity and MASH. Innovent's mazdutide, another dual GLP-1/glucagon agonist, gained regulatory approval in China. Eli Lilly's retatrutide extended the concept to a triple GLP-1/GIP/glucagon agonist. None of these molecules is oxyntomodulin, but every one of them owes its pharmacological rationale to the Bloom group's two-decade interrogation of OXM biology.

How It Works

Oxyntomodulin is a natural gut hormone released after meals that does two jobs at once: it tells your brain you're full (the GLP-1 side) and it tells your liver to burn energy (the glucagon side). Doing both simultaneously is why researchers have spent two decades trying to build drugs around it — single-receptor drugs like semaglutide only cover the first job.

Oxyntomodulin is cleaved from preproglucagon by prohormone convertase 1/3 in intestinal L-cells and secreted postprandially in proportion to nutrient load. The 37-residue peptide comprises the full 29-residue glucagon sequence with an 8-residue C-terminal extension ('Lys-Arg-Asn-Arg-Asn-Asn-Ile-Ala'). It is a balanced but modest-potency agonist at the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR), with reported in vitro potency lower than native GLP-1 at GLP-1R and lower than native glucagon at GCGR — but the simultaneous activation of both receptors produces a distinct physiologic profile. GLP-1R agonism drives hypothalamic and brainstem satiety signaling, delays gastric emptying, and enhances glucose-dependent insulin secretion; GCGR agonism on hepatocytes increases resting energy expenditure, promotes hepatic fat oxidation, and (at higher signaling levels) drives glycogenolysis. Native OXM is rapidly degraded by DPP-4 and has a circulating half-life on the order of minutes, which is why human studies rely on IV infusion or multiple-daily subcutaneous injection and why the drug programs derived from OXM (cotadutide, survodutide, mazdutide, retatrutide — the latter adding GIP agonism) all involve extensive sequence and acylation modifications to extend half-life to days or weeks. Rodent work using glucagon receptor antagonism has demonstrated that the energy-expenditure component of OXM's weight-loss effect depends on intact glucagon receptor signaling, while the food-intake component is primarily GLP-1R-mediated.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Oxyntomodulin:

• 01Long-term efficacy and safety of chronic dual GLP-1/glucagon agonism — native OXM trials were weeks-long; the longer-duration data come from the engineered analogs (cotadutide, survodutide), and whether native-OXM-like kinetics would differ is unresolved.
• 02Optimal GLP-1R vs. GCGR potency balance — native OXM is roughly balanced but modest-potency at both receptors; the engineered dual agonists span a range of balance ratios, and the therapeutic optimum is still being defined.
• 03Cardiovascular outcomes for the dual-agonist class — dedicated CVOTs for survodutide and cotadutide are in progress; whether the CV benefit profile matches selective GLP-1 receptor agonists (LEADER, SUSTAIN-6, SELECT) is unknown.
• 04MASH/MASLD outcomes — the GCGR component of dual agonists is theoretically favorable for hepatic fat oxidation, and dedicated MASH trials (cotadutide, survodutide) are ongoing.
• 05Lean mass preservation — whether the energy-expenditure component of dual agonism alters body-composition outcomes relative to selective GLP-1 agonism is incompletely characterized.
• 06Role of non-peptide small-molecule dual agonists — whether the receptor-level pharmacology of OXM can be recapitulated in oral small molecules is an active medicinal-chemistry question.

Forms & Administration

In published human research, native oxyntomodulin has been administered as an intravenous infusion (single-session mechanistic studies) or as thrice-daily subcutaneous injection 30 minutes before meals (the 4-week Wynne et al. weight-loss protocol). There is no commercially approved formulation of native OXM; the molecule's short half-life makes chronic dosing impractical without engineered modifications. Patients seeking the clinical benefits of dual GLP-1/glucagon agonism should look to the engineered analogs (survodutide, cotadutide, mazdutide) rather than native OXM. All injectable peptides should only be administered under the guidance of a qualified healthcare provider.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Native oxyntomodulin is not FDA-approved for any indication. The doses cited are taken from published research protocols, not prescribing guidance, and are not intended to be applied outside a research setting.

Timeline of Effects

Common Questions

Who Oxyntomodulin Is NOT For

Drug & Supplement Interactions

Dedicated drug-interaction studies for native oxyntomodulin have not been conducted because it is not an approved therapeutic. The best available proxies come from the GLP-1 receptor agonist class and the engineered dual-agonist analogs. Delayed gastric emptying from GLP-1R activity alters absorption of co-administered oral drugs, with particular relevance for narrow-therapeutic-index agents (warfarin, oral contraceptives, levothyroxine, antiepileptics). Concurrent use with insulin or insulin secretagogues raises hypoglycemia risk on the GLP-1R side while the GCGR side may offset this with hepatic glucose mobilization — net clinical effect is unpredictable and requires close monitoring. Investigational dual agonists (cotadutide, survodutide) have interaction data published in their respective trial programs; those should be consulted rather than extrapolated from native OXM. Concurrent use with other GLP-1 or amylin receptor agonists has not been studied and is not appropriate outside a controlled trial.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions